Slide 1: Orion Interim Report Q1/2014
Orion Interim Report Q1/2014 29 April 2014 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: First marketing authorisations in Europe for Bufomix Easyhaler
First marketing authorisations in Europe for Bufomix Easyhaler® • Net sales similar to comparative period • Operating profit slightly lower than in previous year as anticipated • Bufomix Easyhaler® gained first marketing authorisations in Europe • Generic competition to Precedex not yet started in U
Slide 4: Net sales and operating profit
Net sales and operating profit Group key figures Q1/2014 Q1/2013 Change % 2013 Net sales, EUR million 245 249 -2% 1,007 Operating profit, EUR million 67 74 -9% 268 Basic earnings per share, EUR 0.37 0.39 -5% 1.46 Cash flow per share before financial items, EUR 0.30 0.07 +319% 1.02 • Net sales simila
Slide 5: Breakdown of net sales
Breakdown of net sales By business division By market area 7% 3% 13% 6% 29% 36% 6% 12% 14% 42% 32% Proprietary Products Specialty Products Animal Health Finland Scandinavia Fermion Other Europe North America Contract manufacturing & other Orion Diagnostica Other countries 5 29 April 2014 Orion Inter
Slide 6: Business Reviews
Business Reviews
Slide 7: Pharmaceuticals business
Pharmaceuticals business Key figures for Pharmaceuticals business Q1/2014 Q1/2013 Change % 2013 Net sales of Pharmaceuticals, EUR million 230 234 -2% 953 Proprietary Products 88 100 -12% 390 Specialty Products 102 96 +7% 385 Animal Health 15 15 +4% 71 Fermion 15 13 +11% 64 Contract manufacturing and
Slide 8: Best-selling pharmaceuticals
Best-selling pharmaceuticals Business Orion’s best-selling pharmaceuticals, EUR million Division Q1/2014 Q1/2013 Change % 2013 1. Stalevo®, Comtess® and Comtan® (Parkinson’s disease) PP 47.2 60.3 -22% 207 2. Simdax® (acute decompensated heart failure) PP 10.7 10.8 -2% 46 3. Precedex® (intensive care
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in Q1/2014 companies in Q1/2014 EUR million • Wholesale EUR 513 million (+3%) 70 60 59 Orion in Finnish human pharmaceuticals market 50 • Sales growth +2% 39 40 • Orion clear market leader 33 –
Slide 10: Review of Parkinson's drugs markets
Review of Parkinson’s drugs markets Overall markets for Parkinson’s drugs in 2013 Market shares of Orion’s branded Parkinson’s drugs 2013 2012 • United States 3) USD 763 million (+6%) Finland 2) 23% 24% • Five largest European markets 1) 3) EUR 986 million (+2%) Sweden 2) 15% 14% • Japan 2) EUR 495
Slide 11: Precedex and dexdor intensive care sedatives
Precedex® and dexdor® intensive care sedatives European sedative market 2013 Breakdown of Precedex USD million Total market value EUR 475 million (+0.4%) markets 350 4% 13% 300 60 +4% 250 58 16% 200 67% 150 +22% 266 100 211 50 Propofol EUR 318 million (+2%) 0 Midazolam EUR 75 million (-7%) 2012 2013
Slide 12: Key clinical pharmaceutical development projects
Key clinical pharmaceutical development projects Project Indication PHASE Registration Easyhaler® budesonide-formoterol Asthma, COPD I II III Registration Stalevo® for Japanese markets 1) Parkinson’s disease I II III Registration Easyhaler® salmeterol-fluticasone Asthma, COPD I II III ORM-12741 (alp
Slide 13: Diagnostics business
Diagnostics business Key figures for Diagnostics business Q1/2014 Q1/2013 Change % 2013 Net sales, EUR million 16 16 +3% 57 Operating profit, EUR million 2.6 2.3 +14% 4.6 • Operating profit grew mainly due to lower operating expenses • QuikRead® tests remained main product 13 29 April 2014 Orion Int
Slide 14: Outlook for 2014 (unchanged)
Outlook for 2014 (unchanged) • Net sales will be at similar level to 2013 (net sales in 2013 were EUR 1,007 million) • Operating profit will be slightly lower than in 2013 (operating profit in 2013 was EUR 268 million) • Group’s capital expenditure will be about EUR 60 million excluding substantial
Slide 15: Orion Calendar 2014
Orion Calendar 2014 • Interim Report January─June 2014 29 July 2014 • Interim Report January─September 2014 21 October 2014 15 29 April 2014 Orion Interim Report Q1/2014
Slide 16: Orion - Building well-being
GRION Building well-being
Slide 17: Orion's financial objectives
Orion’s financial objectives Orion’s financial objectives are: • Ensuring financial stability • Profitable growth The objectives are achieved through: • Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio. • Maintaining profitabi
Slide 18: Key figures by quarter
Key figures by quarter EUR million Net sales EUR million Operating profit 1,200 300 1,000 250 60 59 53 66 254 273 800 236 Q4 200 65 Q4 215 76 71 67 600 246 237 Q3 150 Q3 211 213 65 Q2 65 Q2 400 100 60 61 227 233 248 207 Q1 Q1 200 50 93 71 79 74 67 215 244 247 249 245 0 0 10 11 12 13 14 10 11 12 13 1
Slide 19: Key figures for 2010-Q1/2014
Key figures for 2010─Q1/2014 Orion’s key figures 2010 2011 2012 2013 Q1/2014 Q1/2013 Change % Net sales, EUR million 849.9 917.9 980.4 1,006.9 245.0 249.4 -1.8% Operating profit, EUR million 254.2 282.9 278.3 267.7 67.4 74.1 -9.1% Profit before taxes, EUR million 252.6 282.0 276.6 264.0 66.5 73.8 -9
Slide 20: Income Statement 2010-Q1/2014
Income Statement 2010─Q1/2014 Formation of profits, EUR million 2010 2011 2012 2013 Q1/2014 Q1/2013 Change % Net sales 849.9 917.9 980.4 1,006.9 245.0 249.4 -1.8% Cost of goods sold -283.2 -305.1 -350.8 -393.5 -95.8 -91.8 +4.4% Gross profit 566.8 612.8 629.6 613.4 149.2 157.6 -5.3% Other operating i
Slide 21: Product protection situation of key products
Product protection situation of key products Key patents or data protection expire Molecule Product Indication Europe USA Japan Stalevo®, November 2012 January Entacapone Parkinson’s disease October 2013 Comtess® and Comtan® October 2013 1) 2015 2) Acute Levosimendan Simdax® decompensated September
Slide 22: Dividend distribution policy
Dividend distribution policy Orion’s dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives. Dividend distribution history EUR 1.60 100% 0.12 EUR 1.40 0.06 95% EUR 1.20 0.10 90%
Slide 23: Slide 23